Sanofi received USPTO Patent US12590167B2 for combination cancer therapies targeting CD38 and TGF-β proteins using specific antibodies. The patent covers compositions and therapeutic methods employing antibodies against these two targets. Key CPC classifications include C07K 16/2896 (CD38 antibodies), C07K 16/22 (TGF-β antibodies), and various formulation codes under A61K. Inventors include Francisco Adrian, Richard C. Gregory, Gary Shapiro, and Helgi Van De Velde.

Patent grants establish intellectual property rights but do not impose immediate compliance obligations on other parties. Competitors developing CD38/TGF-β combination therapies should review this patent for potential licensing needs or freedom-to-operate considerations. The patent's existence may affect research and development strategies in the oncology antibody space. No specific filing deadlines or regulatory responses are required.